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Sir,
In a recently published paper in your journal Nissan et al (2006),
following the commonly used definition, described ‘a molecule
expressed in all tumour cells but not in normal human tissues’ as
an ideal marker for minimal residual disease detection. In
numerous studies based on this definition, the expression of
markers thought to characterise disseminated cancer cells in the
peripheral blood, bone marrow or nodules is analysed against the
results obtained in the relevant tissue obtained from healthy
donors. We raise an issue that healthy donor tissues are not
adequate controls.
The same volume of BJC publishes a paper (one of a series) on
the association of cancer patients’ outcomes with the inflamma-
tion-based prognostic score (Crumley et al, 2006). This and many
other studies clearly indicate the presence and importance of a
systemic inflammation in cancer patients, implying the very likely
presence of activated lymphoid cells in blood, bone marrow or
nodules. Yet, this phenomenon is evidently ignored in many
studies on disseminated cancer cell RT–PCR detection. As we have
shown, many of the so-called tumour markers (squamous-cell
carcinoma antigen, epidermal growth factor receptor, mammaglo-
bin and small breast epithelial mucin) are expressed in normal
peripheral blood lymphocytes following polyclonal activation
in vitro (unpublished data). Similarly, other researchers have
demonstrated that some marker expression is inducible by
cytokines in lymphoid cells from patients without epithelial cancer
(Jung et al, 1998, Kru ¨ger et al, 2001). Therefore, a positive RT–PCR
result may not necessarily indicate the presence of a cancer cell,
but of an activated, inflammatory cell instead. As a result, RT–PCR
detection, characterised by high sensitivity, shows low specificity.
Consequently, the last decade’s constant attempts to apply RT–
PCR for micrometastasis detection have so far failed to produce a
commonly accepted, routinely applied diagnostic method.
The proper assessment of new tumour markers should consider
the inflammation-induced expression. The marker expression in
nonmalignant inflammatory diseases would be informative and
this is an interesting issue for basic science studies, but it
represents an unrealistic approach while validating new molecular
markers for metastatic cancer cell detection, as each new marker
would require studies of peripheral blood, bone marrow, and
nodules of numerous untreated patients. Instead, a simple model
of lymphoid cell activation, such as in vitro mitogen-stimulated
normal peripheral blood cells could serve for testing the specificity
of new markers.
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